The switch from fetal to adult hemoglobin

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 1, 2013, Pages

  Sankaran, Vijay G ^a,b,c   Orkin, Stuart H ^a,d,e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL11A PROTEIN, HUMAN; CARRIER PROTEIN; ERYTHROID KRUPPEL LIKE FACTOR; ERYTHROID KRUPPEL-LIKE FACTOR; HEMOGLOBIN A; HEMOGLOBIN F; KRUPPEL LIKE FACTOR; MYBBP1A PROTEIN, HUMAN; NUCLEAR PROTEIN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; REPRESSOR PROTEIN;

ADULT; ARTICLE; BETA THALASSEMIA; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; SICKLE CELL ANEMIA; TRANSCRIPTION INITIATION;

ADULT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; CARRIER PROTEINS; FETAL HEMOGLOBIN; HEMOGLOBIN A; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTIONAL ACTIVATION;

MLCS; MLOWN;

EID: 84878411727     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a011643     Document Type: Article

References (98)

1. Aerbajinai W., Zhu J, Kumkhaek C, Chin K, Rodgers GP. 2009. SCF induces γ-globin gene expression by regulating downstream transcription factor COUP-TFII. Blood 114: 187-194.
2. Arnaud L., Saison C, Helias V, Lucien N, Steschenko D, Giarratana M.C., Prehu C, Foliguet B, Montout L, de Brevern A.G., et al. 2010. A dominant mutation in the gene encoding the erythroid transcription factor KLF1 causes a congenital dyserythropoietic anemia. Am J Hum Genet 87: 721-727.
3. Atweh G., Fathallah H. 2010. Pharmacologic induction of fetal hemoglobin production. Hematol Oncol Clin North Am 24: 1131-1144.
4. Banzon V., Ibanez V, Vaitkus K, Ruiz MA, Peterson K, DeSimone J, Lavelle D. 2011. siDNMT1 increases γ-globin expression in chemical inducer of dimerization (CID)-dependent mouse βYAC bone marrow cells and in baboon erythroid progenitor cell cultures. Exp Hematol 39: 26-36 e21.
5. Bard H., Prosmanne J. 1985. Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. Pediatrics 75: 1143-1147.
6. Benz Jr. EJ. 1982. Clinical management of gene expression. N Engl J Med 307: 1515-1516.
7. Borg J., Papadopoulos P, Georgitsi M, Gutierrez L, Grech G, Fanis P., Phylactides M, Verkerk AJ, van der Spek PJ, Scerri CA, et al. 2010. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 42: 801-805.
8. Bradner J.E., Mak R, Tanguturi SK, Mazitschek R, Haggarty S.J., Ross K, Chang CY, Bosco J, West N, Morse E., et al. 2010. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci 107: 12617-12622.
9. Campbell A.D., Cui S, Shi L, Urbonya R, Mathias A, Bradley K., Bonsu KO, Douglas RR, Halford B, Schmidt L., et al. 2011. Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes. ProcNatl Acad Sci 108: 18808-18813.
10. Cantor A.B., Orkin SH. 2002. Transcriptional regulation of erythropoiesis: An affair involving multiple partners. Oncogene 21: 3368-3376.
11. Cao H., Stamatoyannopoulos G, Jung M. 2004. Induction of human γ globin gene expression by histone deacetylase inhibitors. Blood 103: 701-709.
12. Carpinelli M.R., Hilton DJ, Metcalf D, Antonchuk JL, Hyland C.D., Mifsud SL, Di Rago L, Hilton AA, Willson T.A., Roberts AW, et al. 2004. Suppressor screen in Mpl2/2 mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling. Proc Natl Acad Sci 101: 6553-6558.
13. Castro O., Brambilla DJ, Thorington B, Reindorf CA, Scott R.B., Gillette P, Vera JC, Levy PS. 1994. The acute chest syndrome in sickle cell disease: Incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84: 643-649.
14. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F., Down J, Denaro M, Brady T, Westerman K, et al. 2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467: 318-322.
15. Chakalova L., Osborne CS, Dai YF, Goyenechea B, Metaxotou-Mavromati A., Kattamis A, Kattamis C, Fraser P. 2005. The Corfu dβ thalassemia deletion disrupts γ-globin gene silencing and reveals post-transcriptional regulation of HbF expression. Blood 105: 2154-2160.
16. Charache S., Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert S.V., McMahon RP, Bonds DR. 1995. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332: 1317-1322.
17. Cui S., Kolodziej KE, Obara N, Amaral-Psarris A, Demmers J, Shi L., Engel JD, Grosveld F, Strouboulis J, TanabeO. 2011. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic β-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol 31: 3298-3311.
18. Dandapani S., Marcaurelle LA. 2010. Current strategies for diversity-oriented synthesis. Curr Opin Chem Biol 14: 362-370.
19. Delmore J.E., Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs H.M., Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. 2011. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146: 904-917.
20. DeSimone J, Heller P, Hall L, Zwiers D. 1982. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci 79: 4428-4431.
21. Dumitriu B., Patrick MR, Petschek JP, Cherukuri S, Klingmuller U., Fox PL, Lefebvre V. 2006. Sox6 cell-autonomously stimulates erythroid cell survival, proliferation, and terminal maturation and is thereby an important enhancer of definitive erythropoiesis during mouse development. Blood 108: 1198-1207.
22. Emambokus N., Vegiopoulos A, Harman B, Jenkinson E, Anderson G., Frampton J. 2003. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. Embo J 22: 4478-4488.
23. Fathallah H., Weinberg RS, Galperin Y, Sutton M, Atweh GF. 2007. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 110: 3391-3397.
24. Filipe A., Li Q, Deveaux S, Godin I, Romeo PH, Stamatoyannopoulos G, Mignotte V. 1999. Regulation of embryonic/ fetal globin genes by nuclear hormone receptors: A novel perspective on hemoglobin switching. EMBO J 18: 687-697.
25. Fritsch E.F., Lawn RM, Maniatis T. 1980. Molecular cloning and characterization of the human β-like globin gene cluster. Cell 19: 959-972.
26. Galanello R., Sanna S, Perseu L, Sollaino MC, Satta S, Lai M.E., Barella S, Uda M, Usala G, Abecasis GR, et al. 2009. Amelioration of Sardinian β0 thalassemia by genetic modifiers. Blood 114: 3935-3937.
27. Galarneau G., Palmer CD, Sankaran VG, Orkin SH, Hirschhorn J.N., Lettre G. 2010. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet 42: 1049-1051.
28. Gallienne A.E., Dreau HM, Schuh A, Old J, Henderson S. 2012. Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults. Haematol 97: 340-343.
29. Groudine M., Eisenman R, Weintraub H. 1981. Chromatin structure of endogenous retroviral genes and activation by an inhibitor of DNA methylation. Nature 292: 311-317.
30. Higgs D.R., WoodWG. 2008. Genetic complexity in sickle cell disease. Proc Natl Acad Sci 105: 11595-11596.
31. Hsieh M.M., Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R., Childs RW, Rodgers GP, Powell JD, Tisdale JF. 2009. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl JMed 361: 2309-2317.
32. Huehns E.R., Hecht F, Keil JV, Motulsky AG. 1964. Developmental hemoglobin anomalies in a chromosomal triplication: D1 trisomy syndrome. Proc Natl Acad Sci 51: 89-97.
33. Jane S.M., Nienhuis AW, Cunningham JM. 1995. Hemoglobin switching in man and chicken is mediated by a heteromeric complex between the ubiquitous transcription factor CP2 and a developmentally specific protein. EMBO J 14: 97-105.
34. Jiang J., Best S, Menzel S, Silver N, Lai MI, Surdulescu GL, Spector T.D., Thein SL. 2006. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 108: 1077-1083.
35. Jones P.A., Taylor SM. 1980. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93.
36. Kar B.C., Satapathy RK, Kulozik AE, Kulozik M, Sirr S, Serjeant B.E., Serjeant GR. 1986. Sickle cell disease in Orissa State, India. Lancet 2: 1198-1201.
37. Koehler AN. 2010. A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol 14: 331-340.
38. Lettre G., Sankaran VG, Bezerra MA, Araujo AS, Uda M, Sanna S., Cao A, SchlessingerD, Costa FF, Hirschhorn JN, et al. 2008. DNA polymorphisms at the BCL11A, HBS1LMYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci 105: 11869-11874.
39. Letvin N.L., Linch DC, Beardsley GP, McIntyre KW, Nathan DG. 1984. Augmentation of fetal-hemoglobin pro-duction in anemicmonkeys by hydroxyurea. NEngl JMed 310: 869-873.
40. Letvin N.L., Linch DC, Beardsley GP, McIntyre KW, Miller B.A., Nathan DG. 1985. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest 75: 1999-2005.
41. Leuschner F., Dutta P, Gorbatov R, Novobrantseva TI, Donahoe JS, Courties G, Lee KM, Kim JI, Markmann JF, Marinelli B., et al. 2011. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29: 1005-1010.
42. +thalassemia. NEngl JMed307:1469-1475.
43. Ley T.J., DeSimone J, Noguchi CT, Turner PH, Schechter AN, Heller P., Nienhuis AW. 1983. 5-Azacytidine increases γglobin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62: 370-380.
44. McGrath K, Palis J. 2008. Ontogeny of erythropoiesis in the mammalian embryo. Curr Top Dev Biol 82: 1-22.
45. McGrath KE, Frame JM, Fromm GJ, Koniski AD, Kingsley PD, Little J, Bulger M, Palis J. 2011. A transient definitive erythroid lineagewith unique regulation of the βglobin locus in the mammalian embryo. Blood 117: 4600-4608.
46. Menzel S., Garner C, Gut I, Matsuda F, Yamaguchi M, Heath S., Foglio M, Zelenika D, Boland A, Rooks H, et al. 2007. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 39: 1197-1199.
47. Michlitsch J.G., Walters MC. 2008. Recent advances in bone marrow transplantation in hemoglobinopathies. Curr Mol Med 8: 675-689.
48. MoelleringRE, CornejoM, DavisTN, DelBiancoC, Aster JC, Blacklow S.C., Kung AL, Gilliland DG, Verdine GL, Bradner JE. 2009. Direct inhibition of the NOTCH transcription factor complex. Nature 462: 182-188.
49. Mukai H.Y., Motohashi H, Ohneda O, Suzuki N, Nagano M, Yamamoto M. 2006. Transgene insertion in proximity to the c-myb gene disrupts erythroid-megakaryocytic lineage bifurcation. Mol Cell Biol 26: 7953-7965.
50. Musallam K.M., Sankaran VG, Cappellini MD, Duca L, Nathan D.G., Taher AT. 2011. Fetal hemoglobin levels and morbidity in untransfused patients with β-thalassemia intermedia. Blood 119: 364-367.
51. Nuinoon M., Makarasara W, Mushiroda T, Setianingsih I, Wahidiyat P.A., Sripichai O, Kumasaka N, Takahashi A, Svasti S., Munkongdee T, et al. 2010. A genome-wide association identified the common genetic variants influence disease severity in β0-thalassemia/hemoglobin E. Hum Genet 127: 303-314.
52. Pace B., Li Q, Peterson K, Stamatoyannopoulos G. 1994. α-Amino butyric acid cannot reactivate the silencedγ gene of the β locus YAC transgenic mouse. Blood 84: 4344-4353.
53. Papayannopoulou T., Torrealba de Ron A, Veith R, Knitter G, Stamatoyannopoulos G. 1984. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. Science 224: 617-619.
54. Perrine R.P., Brown MJ, Clegg JB, Weatherall DJ, May A. 1972. Benign sickle-cell anaemia. Lancet 2: 1163-1167.
55. Perrine S.P., Greene MF, Faller DV. 1985. Delay in the fetal globin switch in infants of diabetic mothers. NEngl J Med 312: 334-338.
56. Perrine S.P., Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska H.E., Cai SP, Vichinsky EP, Olivieri NF. 1993. A short-term trial of butyrate to stimulate fetal-globingene expression in the β-globin disorders. N Engl J Med 328: 81-86.
57. Perrine S.P., Olivieri NF, Faller DV, Vichinsky EP, Dover GJ, Ginder GD. 1994. Butyrate derivatives. New agents for stimulating fetal globin production in the β-globin disorders. Am J Pediatr Hematol Oncol 16: 67-71.
58. Persons DA. 2009. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Hematology 2009: 690-697.
59. Peschle C., Mavilio F, Care A, Migliaccio G, Migliaccio AR, Salvo G., Samoggia P, Petti S, Guerriero R, Marinucci M, et al. 1985. Haemoglobin switching in human embryos: Asynchrony of z → α and 1 → γ-globin switches in primitive and definite erythropoietic lineage. Nature 313: 235-238.
60. Platt OS. 2008. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 358: 1362-1369.
61. Platt O.S., Orkin SH, Dover G, Beardsley GP, Miller B, Nathan DG. 1984. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74: 652-656.
62. Platt O.S., ThoringtonBD, BrambillaDJ, MilnerPF, RosseWF, Vichinsky E., Kinney TR. 1991. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325: 11-16.
63. Platt O.S., Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg M.H., Klug PP. 1994. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330: 1639-1644.
64. Porter J.B., Shah FT. 2010. Iron overload in thalassemia and related conditions: Therapeutic goals and assessment of response to chelation therapies. Hematol Oncol Clin North Am 24: 1109-1130.
65. Premawardhena A., Fisher CA, Olivieri NF, de Silva S, Arambepola M., Perera W, O'Donnell A, Peto TE, Viprakasit V., Merson L, et al. 2005. Haemoglobin E β thalassaemia in Sri Lanka. Lancet 366: 1467-1470.
66. SankaranVG, Nathan DG. 2010a. Reversing the hemoglobin switch. N Engl J Med 363: 2258-2260.
67. Sankaran V.G., Nathan DG. 2010b. Thalassemia: An overview of 50 years of clinical research. Hematol Oncol Clin North Am 24: 1005-1020.
68. Sankaran V.G., Sapp MV. 2012. Persistence of fetal hemoglobin expression in an older child with trisomy 13. J Pediatr 160: 352.
69. Sankaran V.G., Menne TF, Xu J, Akie TE, Lettre G, Van Handel B., Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. 2008. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322: 1839-1842.
70. Sankaran V.G., Xu J, Ragoczy T, Ippolito GC, Walkley CR, Maika S.D., Fujiwara Y, Ito M, Groudine M, Bender MA, et al. 2009. Developmental and species-divergent globin switching are driven by BCL11A. Nature 460: 1093-1097.
71. Sankaran V.G., Xu J, Orkin SH. 2010. Advances in the understanding of haemoglobin switching. Brit J Haematol 149: 181-194.
72. Sankaran V.G., Menne J, Heller R. 2011a. Heterozygous disruption of human SOX6 is insufficient to impair erythropoiesis or silencing of fetal hemoglobin. Blood 117: 4396-4397.
73. Sankaran V.G., Menne TF, Scepanovic D, Vergilio JA, Ji P, Kim J., Thiru P, Orkin SH, Lander ES, Lodish HF. 2011b. MicroRNA-15a and-16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci 108: 1519-1524.
74. Sankaran V.G., Xu J, Byron R, Greisman HA, Fisher C, Weatherall D.J., Sabath DE, Groudine M, Orkin SH, Premawardhena A., et al. 2011c. A functional element necessary for fetal hemoglobin silencing. N Engl J Med 365: 807-814.
75. Satta S., Perseu L, Moi P, Asunis I, Cabriolu A, Maccioni L, Demartis F.R., Manunza L, Cao A, Galanello R. 2011. Compound heterozygosity for KLF1 mutations associated with remarkable increase of fetal hemoglobin and red cell protoporphyrin. Haematologica 96: 767-770.
76. Sher G.D., Ginder GD, Little J, Yang S, Dover GJ, Olivieri NF. 1995. Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N Engl J Med 332: 1606-1610.
77. Stadhouders R., Thongjuea S, Andrieu-Soler C, Palstra RJ, Bryne J.C., van den Heuvel A, Stevens M, de Boer E, Kockx C., van der Sloot A, et al. 2011. Dynamic longrange chromatin interactions control Myb proto-oncogene transcription during erythroid development. EMBO J 31: 986-999.
78. Steinberg M.H., Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A., Orringer E, Bellevue R, Olivieri N, Eckman J, et al. 2003. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 289: 1645-1651.
79. TanabeO, Katsuoka F, CampbellAD, SongW, Yamamoto M, Tanimoto K., Engel JD. 2002. An embryonic/fetal β-type globin gene repressor contains a nuclear receptor TR2/ TR4 heterodimer. EMBO J 21: 3434-3442.
80. Tanabe O., McPhee D, Kobayashi S, Shen Y, Brandt W, Jiang X., Campbell AD, Chen YT, Chang C, Yamamoto M, et al. 2007. Embryonic and fetal β-globin gene repression by the orphan nuclear receptors, TR2 and TR4. EMBO J 26: 2295-2306.
81. Thein S.L., Menzel S, Peng X, Best S, Jiang J, Close J, Silver N, Gerovasilli A., Ping C, Yamaguchi M, et al. 2007. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci 104: 11346-11351.
82. Uda M., Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W., Usala G, Busonero F, Maschio A, Albai G, et al. 2008. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci 105: 1620-1625.
83. van der Ploeg LH, Flavell RA. 1980. DNA methylation in the human γdβ-globin locus in erythroid and nonerythroid tissues. Cell 19: 947-958.
84. van Dijk TB, Gillemans N, Pourfarzad F, van Lom K, von Lindern M., Grosveld F, Philipsen S. 2010. Fetal globin expression is regulated by Friend of Prmt1. Blood 116: 4349-4352.
85. Wahlberg K., Jiang J, Rooks H, Jawaid K, Matsuda F, Yamaguchi M., Lathrop M, Thein SL, Best S. 2009. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 114: 1254-1262.
86. Watson J. 1948. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci 215: 419-423.
87. Weatherall DJ. 2001. Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias. Nat Rev 2: 245-255.
88. Weatherall D.J., Clegg JB. 2001. The thalassaemia syndromes, 4th ed. Blackwell Science, Malden, MA.
89. Weatherall D., Akinyanju O, Fucharoen S, Olivieri N, Musgrove P. 2006. Inherited disorders of hemoglobin. In Disease control priorities in developing countries, 2nd ed., pp. 663-680. Oxford University Press, New York.
90. + cells after lentiviral vector-mediated gene transfer. Blood 117: 2817-2826.
91. Xu J., Sankaran VG, Ni M, Menne TF, Puram RV, Kim W, Orkin SH. 2010. Transcriptional silencing of γ-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev 24: 783-798.
92. Xu J., Peng C, Sankaran VG, Shao Z, Esrick EB, Chong BG, Ippolito G.C., Fujiwara Y, Ebert BL, TuckerPW, et al. 2011. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 334: 993-996.
93. Zhao Q., ZhouW, Rank G, Sutton R, Wang X, Cumming H, Cerruti L., Cunningham JM, Jane SM. 2006. Repression of human γ-globin gene expression by a short isoform of the NF-E4 protein is associated with loss of NF-E2 and RNA polymerase II recruitment to the promoter. Blood 107: 2138-2145.
94. Zhou W., Zhao Q, Sutton R, Cumming H, Wang X, Cerruti L., Hall M, Wu R, Cunningham JM, Jane SM. 2004. The role of p22 NF-E4 in human globin gene switching. J Biol Chem 279: 26227-26232.
95. Zhou D., Liu K, Sun CW, Pawlik KM, Townes TM. 2010. KLF1 regulates BCL11A expression and γ-to β-globin gene switching. Nat Genet 42: 742-744.
96. Zuber J., Rappaport AR, LuoW, Wang E, Chen C, Vaseva AV, Shi J., Weissmueller S, Fellmann C, Taylor MJ, et al. 2011a. An integrated approach to dissecting oncogene addiction implicates aMyb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev 25: 1628-1640.
97. Zuber J., Shi J, Wang E, Rappaport AR, Herrmann H, Sison E.A., Magoon D, Qi J, Blatt K, Wunderlich M, et al. 2011b. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.
98. Zuk O., Hechter E, Sunyaev SR, Lander ES. 2012. The mystery of missing heritability: Genetic interactions create phantom heritability. ProcNatl Acad Sci 109: 1193-1198.